FDL169 is a new CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A phase 2 study to test the safety of this compound on those with two copies of the F508del CFTR mutation will begin soon.
This program is sponsored by Flatley Discovery Lab. It is being conducted within the Cystic Fibrosis Foundation's Therapeutics Development Network.
Contact us about FDL169 >